Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients

BackgroundImmune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.MethodsWe conducted a prospective observational study of t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Elena Poddubskaya, Maria Suntsova, Marina Lyadova, Daniil Luppov, Anastasia Guryanova, Vladimir Lyadov, Andrew Garazha, Maksim Sorokin, Anna Semenova, Vitaly Shatalov, Maria Biakhova, Alexander Simonov, Aleksey Moisseev, Anton Buzdin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint therapy pembrolizumab ipilimumab nivolumab non-small cell lung cancer RNA sequencing
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1493877/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients

Similar Items